Forxiga CHMP opinion for symptomatic chronic HF
19 December 2022 7:00 GMT Forxiga recommended for approval in the EU by CHMPfor symptomatic chronic heart failure If approved, Forxiga will be the first heart failure therapy indicated across the full ejection fraction range with proven mortality reduction AstraZeneca's Forxiga (dapagliflozin) has been recommended for approval in the European Union (EU) to extend the indication for heart failure with reduced ejection fraction (HFrEF) to cover patients across the full spectrum of left ventricular ejection fraction (LVEF) including HF with mildly reduced and preserved ejection